Chimerism does not predict for outcome after alemtuzumab based conditioning.
Michaelis
L
L
Lin
S
S
Joseph
L
L
Artz
A S
AS
Kline
J
J
Pollyea
D
D
Stock
W
W
Rich
E
E
Collins-Jones
D
D
Casey
B
B
Del Cerro
P
P
van Besien
K
K
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D006086:Graft vs Host Disease / Q000517:prevention & control; D019337:Hematologic Neoplasms / Q000276:immunology / Q000628:therapy; D006801:Humans; D033581:Stem Cell Transplantation; D018183:Transplantation Chimera / Q000276:immunology*; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000074323:Alemtuzumab